Eliminate charge for a reduction in
expected insurance recoveries .06 -
Include pro forma as if the ICOS
acquisition was completed on
January 1, 2006 - (.03)
E.P.S. (pro forma adjusted) $.91 $.77 18 %
In the third quarter of 2007, Zyprexa sales totaled $1.166 billion, an 8 percent increase compared with the third quarter of 2006. U.S. sales of Zyprexa increased 4 percent, to $540.6 million, due to higher prices, offset in part by declining demand. Zyprexa sales in international markets increased 11 percent, to $625.6 million, driven by the impact of foreign exchange rates and increased demand.
For the third quarter of 2007, Cymbalta generated $513.2 million in sales, an increase of 47 percent compared with the third quarter of 2006. U.S. sales of Cymbalta increased 45 percent, to $444.3 million, due to strong demand. Sales outside the U.S. were $68.9 million, an increase of 64 percent, driven primarily by higher demand, as well as the impact of foreign exchange rates and higher prices. Cymbalta continues to gain market share in the U.S. and internationally.
Gemzar had sales totaling $394.4 million for the third quarter, an increase of 11 percent from the third quarter of 2006. Sales in the U.S. increased 9 percent, to $166.5 million, due to higher prices and demand, while sales outside the U.S. increased 13 percent, to $227.9 million, as a result of increased demand and the impact of foreign exchange rates.
For the third quarter of 2007, worldwide Humalog sales increased 12
percent, to $362.5 million. Sales in the U.S. increased 9 percent to $216.1
million, driven by increased prices and higher demand. Sales outside the
U.S. increased 19 percen
|SOURCE Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved